Symbols

HALO

Halozyme Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 2

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HALO

Halozyme Therapeutics, Inc.

A biopharmaceutical company that develops recombinant human enzymes and novel oncology therapies for the tumor microenvironment

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

05/10/2007

Exchange

NASDAQ Stock Exchange

Full-time Employees

350

Fiscal Year Ends

12-31

Website

www.halozyme.com

Security Type

Common stock

Office address

12390 El Camino Real, San Diego, California, 92130

Business

Introduction

Halozyme Therapeutics, Inc., is a biopharmaceutical company founded in 1998. In November 2007, the company was reorganized and registered in Delaware (previously registered in Nevada). The company is committed to the development and commercialization of innovative products. The company studies extracellular matrix, extracellular regions, including cell migration, signaling and survival. Over the years, the company has developed unique scientific expertise that allows it to pursue treatments that focus on environmental development.

Earnings Call

Q1/2025

Estimate EPS0.94

Actual EPS1.11

Estimate Revenue230.18M

Actual Revenue265.00M

Halozyme's Q1 2025: Contradictions Unveiled in Patent Litigation, ENHANZE Business, and Partnership Confidence

May 07,2025 07:28·
Earnings Decrypt

Company Financials

EPS

HALO has released its 2025 Q1 earnings. EPS was reported at 1.11, versus the expected 0.94, beating expectations. The chart below visualizes how HALO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HALO has released its 2025 Q1 earnings report, with revenue of 264.86M, reflecting a YoY change of 35.22%, and net profit of 118.09M, showing a YoY change of 53.72%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.